AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsInformation ScienceHealth Care
CisplatinInjections, IntraperitonealAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsPlatinumDrug Administration ScheduleOvarian NeoplasmsDrug Resistance, NeoplasmDose-Response Relationship, DrugLung NeoplasmsEtoposideDisease Models, AnimalCombined Modality TherapyFluorouracilDeoxycytidineCell Line, TumorVinblastineDNA AdductsMice, Inbred BALB CTreatment OutcomePaclitaxelDrug SynergismApoptosisRats, WistarInfusions, ParenteralHead and Neck NeoplasmsSurvival AnalysisCarboplatinTime FactorsIfosfamideDoxorubicinVomitingCarcinoma, Squamous CellRats, Sprague-DawleyDrug Screening Assays, AntitumorInfusions, IntravenousCarcinoma, Non-Small-Cell LungTumor Cells, CulturedTaxoidsMice, Inbred C57BLCell SurvivalMitomycinLeukopeniaSurvival RateKidneyMice, NudeLiverDisease-Free SurvivalPeritoneal NeoplasmsAntineoplastic Agents, PhytogenicTesticular NeoplasmsAdenocarcinomaBleomycinPeritoneal CavityNauseaDNA DamageSpleenCamptothecinMice, Inbred ICRNeoplasm StagingVindesineOxonic AcidStomach NeoplasmsRandom AllocationCarcinoma, Small CellLethal Dose 50NeutropeniaInjections, IntravenousPeritoneumAdministration, OralTegafurNeoplasms, Germ Cell and EmbryonalGlutathioneCyclophosphamideMice, Inbred StrainsDrug ResistanceDNA RepairPlant ExtractsBlood Urea NitrogenXenograft Model Antitumor AssaysNeoplasm TransplantationGerminomaDrug EvaluationCarcinomaNeoplasmsBlotting, WesternNeoplasm Recurrence, LocalCell ProliferationDrug InteractionsEsophageal NeoplasmsMesotheliomaChemotherapy, AdjuvantAntimetabolites, AntineoplasticAscitic FluidDrug CombinationsAntiemeticsMaximum Tolerated DoseEpirubicinLipopolysaccharidesImmunohistochemistry
ChemotherapyNephrotoxicityCycles of cisplatinTumorSingle doseAcute kidneyRenalToxicityRatsMiceMalignant pleural mesotheliomaCDDPOxidative stressInjectionDrugsSignificantlyGastricTumourAqueousVivoDaysKidney injuryMolecular mechanismsLungDosagePatientsNSCLCWidelyDosesTreatmentSurvivalGroupSevereADMINISTRATIONNormalExtentEffectCellsActiveAnimal modelExpressionSubjectComplexActivity
Chemotherapy5
  • Chemotherapy, including cisplatin (CDDP), remains a potent treatment for patients with late-stage liver cancer [ 2 , 3 ]. (ijbs.com)
  • Cisplatin has been used as a standard agent of combination chemotherapy in several cancers, such as nasopharyngeal, lung, and ovarian cancer. (thieme-connect.com)
  • In fact, the prevalence of cisplatin-induced kidney damage was 34% after fourth cycles and 52% after six cycles of cisplatin chemotherapy in adult cancer patients treated with cisplatin at a dose of ≥60 mg/m 2 at Dharmais National Cancer Hospital, Jakarta, Indonesia [ 6 ]. (thieme-connect.com)
  • We show that loss of the DNA repair protein XPA markedly augments the synthetic lethality between MK2 and p53, enhancing anti-tumor responses alone and in combination with cisplatin chemotherapy. (nature.com)
  • Intensification of intra-arterial chemotherapy with high-dose cisplatin and concomitant reduction of toxicity under the conditions of the head and neck was aimed at by combination of antineoplastic activity and embolizing effect in the same pharmacon. (omicsdi.org)
Nephrotoxicity3
  • Previous studies have demonstrated that curcumin at a dose of 100 mg/kg orally in mice and 60 mg/kg in rats reduced concentration of tumor necrosis factor (TNF)-α and inhibited oxidative stress in cisplatin-induced nephrotoxicity [ 7 ] [ 8 ]. (thieme-connect.com)
  • Preloading magnesium attenuates cisplatin-associated nephrotoxicity: pilot randomized controlled trial (PRAGMATIC study). (omicsdi.org)
  • We investigated whether preloading with magnesium prevents nephrotoxicity with a low-dose weekly cisplatin regimen. (omicsdi.org)
Cycles of cisplatin1
  • The cisplatin group received 2 cycles of cisplatin (2.5 mg/kg/day for 5 days with 16 days of recovery) intraperitoneally, and the cisplatin + cooling group received the same regimen of cisplatin with a cooling protocol: cooling induction for 30 minutes before injection and cooling for 60 minutes after injection. (psu.edu)
Tumor5
  • However, co-culture in vitro experiments and co-implantation in vivo experiments showed that the combination of low doses of cisplatin (10 μM) and low doses of pirfenidone (0.5 mg/mL), in both CAFs and tumors, lead to increased cell death and decreased tumor progression, respectively. (biomedcentral.com)
  • After 6 days of H22 cell injection, tumor mice had been intraperitoneally treated with DMSO, cisplatin and MPEE. (esiservizi.com)
  • The overall cisplatin tumor response rate and survival were comparable between groups. (omicsdi.org)
  • Based on a previous animal test which indicates the optimal dose of 1mg/kg of D-fraction for anti-tumor activity, ten times more dosage was employed intraperitoneally for 30 days. (orthomolecular.org)
  • The coadministration of cisplatin with PCNs induced a synergistic suppression of tumor growth by improving drug delivery as evidenced by increased blood prefusion and decreased vascular permeability. (biomedcentral.com)
Single dose5
  • CKD mice were induced by a single dose of cisplatin 10 mg/kg, intraperitoneally. (biomedcentral.com)
  • The first group, which served as the control, was administered physiological saline (2.5 cc/day, 5 days) intraperitoneally (IP), while group A was administered cisplatin (6 mg/kg BW/single dose) plus physiological saline IP. (deu.edu.tr)
  • Curcumin was given at a dose of 100 mg/kg orally for nine days, starts one week before giving a single dose of cisplatin. (thieme-connect.com)
  • Group-3 (cisplatin group) was IP received 5 mg/kg cisplatin single dose. (omicsdi.org)
  • Group-4 (rutin and cisplatin group) was orally administrated 30 mg/kg rutin dissolved in water for 14 days with a single dose of 5 mg/kg cisplatin IP on day ten. (omicsdi.org)
Acute kidney6
  • Cisplatin is widely recommended in combination for the treatment of tumors, thus inevitably increasing the incidence of cisplatin-induced acute kidney injury. (ijbs.com)
  • Here, we investigated the mechanism underlying both BNIP3-mediated and PINK1-PARK2-mediated mitophagy-induced attenuation of ferroptosis in cisplatin-induced acute kidney injury. (ijbs.com)
  • Nephrotoxic drugs, such as antibiotics (gentamicin), diuretics (furosemide), chemotherapeutic drugs (cisplatin) and calcineurin inhibitors (tacrolimus), induce acute kidney injury [ 1 ]. (ijbs.com)
  • During cisplatin treatment, approximately 20%-30% of patients develop acute kidney injury [ 7 ]. (ijbs.com)
  • The mechanism of cisplatin-induced acute kidney injury includes oxidative stress, mitochondrial dysfunction, and endoplasmic reticulum stress, which result in apoptosis, necrosis and ferroptosis of renal tubular epithelial cells, causing rapid loss of kidney function [ 8 - 11 ]. (ijbs.com)
  • Elucidating the precise molecular mechanisms underlying cisplatin-induced acute kidney injury will provide evidence for future treatment. (ijbs.com)
Renal5
  • Cumulative renal toxicity associated with cisplatin is severe. (nih.gov)
  • In conclusion, it was found that the administration of L. fermentum probiotic, and particularly its postbiotic in cisplatin-induced CKD mice, showed promising effects and could successfully improve renal function in the animal model of CKD. (biomedcentral.com)
  • Thus, the present study elucidated a novel mechanism by which both BNIP3-mediated and PINK1-PARK2-mediated mitophagy protects against cisplatin-induced renal tubular epithelial cell ferroptosis through the ROS/HO1/GPX4 axis. (ijbs.com)
  • Over the last few decades, it has been studied that the mechanisms of cisplatin-induced kidney damage are complex and involved numerous cellular and molecular processes including inflammation, apoptosis, accumulation of cisplatin in renal tubular cells via renal drug transporters, Ctr1 and OCT2, and involvement of mitogen-activated protein kinases (MAPK) pathways [ 3 ] [ 4 ]. (thieme-connect.com)
  • 9 ] reported curcumin administration provided protection against cisplatin-induced renal tubular cell apoptosis. (thieme-connect.com)
Toxicity1
  • Objective To investigate the protective effects of scrotal cooling on cisplatin-induced gonadal toxicity in an animal model. (psu.edu)
Rats5
  • Different age groups of Wistar rats (aged 3, 7, 11 and 24 weeks) were given CP intraperitoneally (6 mg/kg) and sacrificed 6 days thereafter. (elsevierpure.com)
  • This study aimed to investigate the molecular mechanisms of protective effects of curcumin against cisplatin-induced kidney inflammation and apoptosis in rats. (thieme-connect.com)
  • Results Cisplatin challenged rats demonstrated kidney injury as shown by reduced creatinine clearance, increased of plasma BUN, plasma creatinine, and kidney MDA, decreased of kidney GSH levels, and kidney histopathology alterations. (thieme-connect.com)
  • Conclusions These data indicate that curcumin has nephroprotective properties against cisplatin-induced kidney damage in rats and this effect is associated with its anti-inflammatory and anti-apoptosis profiles, in addition to its antioxidant. (thieme-connect.com)
  • The aim of this study was to determine the potential preventive effects of rutin on the brain of cisplatin- neurotoxic rat model.Forty rats were divided into four groups. (omicsdi.org)
Mice6
  • Mice in control group were given an injection of 2 mL normal saline intraperitoneally. (psu.edu)
  • Results The volume of the testes, tubules, and epithelium was reduced between 61% and 66%, and the number of the spermatogonia, spermatocytes, round spermatids, and long spermatids was reduced between 70% and 93% in cisplatin group compared with that of control mice. (psu.edu)
  • The volume and number of the cells were reduced in the cisplatin + cooling group but to a lesser extent compared with those of mice in the cisplatin group. (psu.edu)
  • Abstract Our aim was to evaluate the effects of cisplatin and dexamethasone alone and combined on gastric contractility and histomorphometry of BALB/c and C57BL/6 mice. (bvsalud.org)
  • The results showed that cisplatin induced mitochondrial injury, ROS release, intracellular iron accumulation, lipid peroxidation and ferroptosis in the kidney, which were aggravated in Bnip3 knockout , Pink1 knockout or Park2 knockout cisplatin-treated mice. (ijbs.com)
  • Experimental Design: To study the synergistic effect of both agents on human cancer xenografts, athymic nude ( Nu/Nu ) mice were used and treated with various combination regimes intraperitoneally. (oncotarget.com)
Malignant pleural mesothelioma2
  • initial treatment, in combination with cisplatin, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery. (nih.gov)
  • Pemetrexed Injection is used in combination with cisplatin as the first treatment for malignant pleural mesothelioma that cannot be removed by surgery or you are not able to have surgery. (pfizermedicalinformation.com)
CDDP2
Oxidative stress1
  • Objective In addition to oxidative stress, inflammation and apoptosis have an important role in the pathogenesis of cisplatin-induced kidney damage. (thieme-connect.com)
Injection5
  • Cisplatin Injection should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. (nih.gov)
  • Cisplatin Injection infusion concentrate is a clear, colorless, sterile aqueous solution. (nih.gov)
  • Each 50 mL or 100 mL amber vial of Cisplatin Injection contains: 1 mg/mL cisplatin, 9 mg/mL sodium chloride, hydrochloric acid and/or sodium hydroxide to adjust pH, and water for injection to a final volume of 50 mL or 100 mL, respectively. (nih.gov)
  • The pH range of Cisplatin Injection is 3.8 to 5.9. (nih.gov)
  • The most common adverse reactions (incidence ≥20%) of pemetrexed for injection when administered with cisplatin are vomiting, neutropenia, anemia, stomatitis/pharyngitis, thrombocytopenia, and constipation. (nih.gov)
Drugs2
Significantly2
  • Compared with untreated and DMSO groups, cisplatin significantly decreased the physique weight but MPEE did not drastically change the physique weight, suggesting that the selected doses of MPEE had no clear side effect (Fig. 9A). (esiservizi.com)
  • Pre-treatment with curcumin significantly ameliorated inflammation and apoptosis induced by cisplatin. (thieme-connect.com)
Gastric2
  • Dexamethasone and cisplatin combined restored the gastric frequency and food intake only in BALB/c, but drug combination reduced the gastric amplitude of contractions in both strains. (bvsalud.org)
  • In conclusion, the mouse strains presented differences in acute effects of cisplatin and dexamethasone alone and combined on gastric function. (bvsalud.org)
Tumour1
  • A control group (n=30) with the same tumour and nodal staging was treated with a usual cisplatin solution (150 mg m(-2) dissolved in 500 ml saline). (omicsdi.org)
Aqueous1
  • Monocomponent chemoembolization in oral and oropharyngeal cancer using an aqueous crystal suspension of cisplatin. (omicsdi.org)
Vivo2
  • Collectively, our results underline that the high activity of JNK/c-Jun-ATF2/Galectin-1 mediates cisplatin resistance in liver cancer and provides an optional scheme for dynamic monitoring of molecular activity in vivo . (ijbs.com)
  • These findings establish a mechanism for co-targeting DNA damage-induced cell cycle checkpoints in combination with repair of cisplatin-DNA lesions in vivo using RNAi nanocarriers, and motivate further exploration of ASL as a generalized strategy to improve cancer treatment. (nature.com)
Days1
  • The complexes between albumin and the platinum from cisplatin do not dissociate to a significant extent and are slowly eliminated with a minimum half-life of five days or more. (nih.gov)
Kidney injury1
  • A multi-age rat model was evaluated to identify a potential age-related difference in kidney injury following administration of cisplatin (CP). (elsevierpure.com)
Molecular mechanisms2
  • However, the molecular mechanisms behind the anti-inflammatory and anti-apoptotic effects of curcumin in the cisplatin-induced kidney damage have not been explored. (thieme-connect.com)
  • Therefore, in this study, we aimed to investigate the possible molecular mechanisms of anti-inflammatory and anti-apoptotic effects of curcumin in cisplatin-induced kidney damage. (thieme-connect.com)
Lung4
  • The effects of pirfenidone alone and in combination with cisplatin on human patient-derived CAF cell lines and non-small cell lung cancer (NSCLC) cell lines were examined. (biomedcentral.com)
  • Purpose To investigate the effect of cisplatin about the growth and metastasis abilities of lung malignancy stem cells (CSCs) via molecular imaging. (sunolmolecular.com)
  • Delivery of siRNA-peptide nanoplexes co-targeting MK2 and XPA to pre-existing p53-deficient tumors in a highly aggressive, immunocompetent mouse model of lung adenocarcinoma improves long-term survival and cisplatin response beyond those of the synthetic lethal p53 mutant/MK2 combination alone. (nature.com)
  • as the first treatment in combination with cisplatin when your lung cancer has spread (advanced NSCLC). (pfizermedicalinformation.com)
Dosage1
  • Cisplatin dosage was 150 mg m(-2), maximum absolute dose 300 mg, maximum amount of fluid 60 ml. (omicsdi.org)
Patients2
  • in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC. (nih.gov)
  • In a standard 3 + 3 phase 1 design for dose escalation, 212 Pb-TCMC-trastuzumab was delivered intraperitoneally less than 4 h after administration of trastuzumab (4 mg/kg intravenously) to patients with peritoneal carcinomatosis who had failed standard therapies. (snmjournals.org)
NSCLC3
  • Furthermore, the combination of cisplatin and pirfenidone in NSCLC cells (A549 and H157 cells) leads to increased apoptosis and synergistic cell death. (biomedcentral.com)
  • Our studies reveal for the first time that the combination of cisplatin and pirfenidone is active in preclinical models of NSCLC and therefore may be a new therapeutic approach in this disease. (biomedcentral.com)
  • Cisplatin is a platinum-based chemotherapeutic drug that has been used as the standard of care in late stages of NSCLC in combination with paclitaxel, vinorelbine, gemcitabine, docetaxel, pemetrexed, or irinotecan [ 20 ]. (biomedcentral.com)
Widely1
  • Cisplatin is widely used chemotherapeutic agent for cancer treatment with limited uses due to its neurotoxic side effect. (omicsdi.org)
Doses2
  • Care must be taken to avoid inadvertent cisplatin overdose due to confusion with carboplatin or prescribing practices that fail to differentiate daily doses from total dose per cycle. (nih.gov)
  • Plasma concentrations of the parent compound, cisplatin, decay monoexponentially with a half-life of about 20 to 30 minutes following bolus administrations of 50 or 100 mg/m 2 doses. (nih.gov)
Treatment2
  • In contrast to our initial hypothesis that the CD133+ cells may become enriched by transient cisplatin treatment, minor decrease of CD133+ cell percentage was found in +Cis cells as compared with ?Cis cells (Number 1c). (sunolmolecular.com)
  • Even though various treatment strategies namely saline hydration and diuresis have been suggested for prevention of cisplatin-induced kidney damage, but its prevalence is still high. (thieme-connect.com)
Survival1
  • In particular, extracellular-regulated kinase (ERK) 1/2, one of the MAPK pathway is considered as an important mediator of signal transduction processes, namely cell survival, cell division, gene expression, and cell metabolism that plays role in injury, death, and inflammation of kidney tubular cells due to cisplatin administration [ 5 ]. (thieme-connect.com)
Group2
  • Sertoli cells were more intact in the cisplatin + cooling group compared with those of the control group. (psu.edu)
  • In addition, curcumin downregulated Ctr1 and OCT2 drug transporters as compared to cisplatin group. (thieme-connect.com)
Severe1
ADMINISTRATION2
Normal3
  • Cisplatin does not undergo the instantaneous and reversible binding to plasma proteins that is characteristic of normal drug-protein binding. (nih.gov)
  • normal (0.5% CMC-Na), cisplatin (CDPP) (7 mg/kg i.p.), and cisplatin+curcumin (CMN100) groups. (thieme-connect.com)
  • A cisplatin suspension in normal saline (5 mg in 1 ml) with precipitation of microembolizing cisplatin crystals was prepared. (omicsdi.org)
Extent1
  • Cisplatin affected spermatids to a greater extent, and Sertoli cells to a lesser extent than the other cells. (psu.edu)
Effect1
  • Neuro-protective effect of rutin against Cisplatin-induced neurotoxic rat model. (omicsdi.org)
Cells1
  • Outcomes Identity of the CSC Features Derived from A549-Luc-C8 Cells in Vitro We initial supervised the impact of cisplatin on CSCs in A549-Luc-C8 cells in vitro. (sunolmolecular.com)
Active1
  • The active ingredient, cisplatin, is a yellow to orange crystalline powder with the molecular formula PtCl 2 H 6 N 2 , and a molecular weight of 300.1. (nih.gov)
Animal model1
  • The current study is aimed to evaluate the efficacy of Limosilactobacillus fermentum ( L. fermentum ) and its postbiotic in an animal model of cisplatin-induced CKD. (biomedcentral.com)
Expression2
  • Mechanistically, the highly activated JNK phosphorylated c-Jun and ATF2 formed a heterodimer to upregulate the expression of Galectin-1, leading to promoting cisplatin resistance in liver cancer. (ijbs.com)
  • Also, cisplatin increased ERK1/2 phosphorylation and NF-κB expression, which subsequently increased mRNA expression of TNF-α, IL-6, KIM-1, NGAL, and Bax/Bcl-2 ratio as well as decreased mRNA expression of IL-10 in kidney tissues. (thieme-connect.com)
Subject1
  • Due to its unique chemical structure, the chlorine atoms of cisplatin are more subject to chemical displacement reactions by nucleophiles, such as water or sulfhydryl groups, than to enzyme-catalyzed metabolism. (nih.gov)
Complex1
  • Cisplatin is a heavy metal complex containing a central atom of platinum surrounded by two chloride atoms and two ammonia molecules in the cis position. (nih.gov)
Activity1
  • The high activity of the JNK promotes poor progression and mediates cisplatin resistance in liver cancer, leading to a poor prognosis of liver cancer. (ijbs.com)